Memantine is recommended for the symptomatic treatment of severe AD as a mono- and combination therapy with cholinesterase inhibitors and should be also considered as possible treatment in moderate AD in the current version of the UK National Institute for Health and Care Excellence (NICE) guidelines of dementia management (Pink et al., 2018). Here, BCHE is linked to Alzheimer disease.